Entasis Therapeutics Holdings, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
REGNRegeneron Pharmaceuticals, Inc. -1.30%569.132.7%$665.84m
ILMNIllumina, Inc. -0.41%319.133.5%$655.78m
AMGNAmgen, Inc. -1.31%228.071.3%$591.35m
ARRYArray BioPharma Inc. 2.52%39.4714.2%$514.82m
GILDGilead Sciences, Inc. -0.68%60.141.0%$503.58m
MRNAModerna, Inc. -2.54%69.500.0%$490.90m
VRTXVertex Pharmaceuticals, Inc. -1.96%210.341.9%$470.25m
IMMUImmunomedics, Inc. 0.09%87.8011.0%$388.12m
NVAXNovavax, Inc. -6.45%92.0296.5%$305.04m
ALXNAlexion Pharmaceuticals, Inc. -3.38%119.812.0%$287.66m
BIIBBiogen, Inc. -1.13%264.101.6%$254.69m
EXASEXACT Sciences Corp. -2.30%100.6520.7%$224.06m
BNTXBioNTech SE -6.67%88.060.0%$210.42m
SRNESorrento Therapeutics, Inc. -4.08%7.891.4%$184.85m
SGENSeagen Inc. 0.51%199.046.0%$170.96m

Company Profile

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA.